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Objective. To evaluate functional outcome of the retrourethral transobturator sling suspension (RTS) in the treatment of stress
urinary incontinence (SUI) caused by prior prostate surgery.Methods. The RTS (AdVance male sling) was implanted in 32 patients
who suﬀered from mild to severe postsurgical-treatment incontinence at the University Hospital Ulm from September 2010 to
September 2011 including 10 patients with prior radiation therapy. Functional data (uroﬂowmetry, daily pad use, and postvoid
residual urine) as well as quality of life with impact of urinary problems (ICIQ-UI SF) were prospectively assessed at baseline and
during followup. Results. After a median followup of 9 months (range, 3–14) the incontinence cure rate (no pad usage) was 56.2%
and the improvement rate (1-2 pads/day or ≥50% reduction) was 21.9%. No improvement was observed in 21.9%. Daily pad
use and ICIQ-UI SF score improved signiﬁcantly. No major perioperative complications occurred. Postoperatively, 15.6% of the
patients exhibited transient acute urinary retention which resolved without further treatment after a maximum of 3 weeks. One
patient underwent sling explantation due to dislocation and persistent perineal pain. Conclusions. The implantation of the RTS is
a safe and eﬀective procedure in selected patients with SUI resulting from prostate surgery.
1.Introduction
Radical prostatectomy is regarded as the gold standard
surgical treatment for organ conﬁned prostate cancer. Even
though the surgical technique has been improved steadily
stress urinary incontinence is a well-known side eﬀect of
this procedure with reported incidence rates of up to 20%
[1, 2]. Another rare reason for postsurgery incontinence
is the transurethral resection (TUR) of the prostate [3].
The artiﬁcial urinary sphincter is still considered to be the
standard surgical treatment for stress incontinence after
prostatesurgerywithgoodlong-termresultsintermsofcon-
tinence and quality of life [4, 5]. However, besides patients’
requirement of mental capacity and ﬁne-motor control to
operate the implanted pump, the signiﬁcant reoperation rate
≥35%duetowell-knowncomplicationssuchascuﬀerosion,
infection, or mechanical problems lead to an establishment
of minimal invasive sling systems for treatment of urinary
incontinence in the last years [6]. The retrourethral transob-
turator sling suspension (RTS), (AdVance male sling, Ameri-
canMedicalSystems,Minnetonka,MN,USA),introducedin
2006, oﬀers a functional approach by relocating the descent
proximal urethra into the original anatomic position and
thus allowing adequate function of the sphincter [7, 8].
Therefore suﬃcient sphincter contraction with or without
complete closure is essential for the success of this approach.
Promising results in recent studies show success rates from
54–80% regarding improved continence with few serious
complications. [9–11]. However, failure rates of up to 36.5%
and even worsening in 9% have been reported [12]. Taking
these objections into account, this study was performed to
prospectively evaluate the functional outcome of the RTS at
our institution.2 ISRN Urology
Table 1: Patient characteristics before sling implantation.
Variable Value
Age at sling implantation, years
Median (range) 70.5 (61–88)
Prostatectomy n (%)
Retropubic 22 (68)
Laparoscopic 3 (9.4)
Perineal 3 (9.4)
TUR-P 6 (12.5)
Pretreatment n (%)
Radiotherapy 10 (31.3)
Bladder neck incision 10 (31.3)
Bulking agents 6 (12.5)
Daily pad use, pads/day
Median (range) 4.0 (2–10)
Mean 5.1
Grade of incontinence, no of patients (%)
Mild: 1-2 pads/day 6
Moderate: 3–5pads/day 18
Severe: ≥6pads/day 8
2. Patientsand Methods
From September 2010 to September 2011, 32 patients with
mild to severe stress urinary incontinence after prostate
surgery were treated with RTS in the Department of
Urology, University Hospital Ulm. The median age was
70.5years (range: 61–88). Twenty-eight patients (87.5%)
had undergone radical prostatectomy for prostate cancer,
the remaining 4 patients (12.5%) had been treated with
transurethral resection of the prostate. The median time
between prostate surgery to sling implantation was 56
months (range, 6–161). The implantation of the male sling
system was performed at least 6months after initial treat-
ment. The patient population comprised 10 men (31.3%)
after additional pelvic radiotherapy. Ten patients (31.3%)
were treated with transurethral incision of the bladder neck
in case of bladder-neck obstruction prior (n = 8) to or
during(n = 2)theimplantationoftheRTS.Sixmen(18.8%)
had been treated with bulking agents without success
before sling implantation. All patients had adequate prior
treatmentbypelvicﬂoormuscletraining.Preoperativework-
up included physical examination, uroﬂowmetry (Qmax),
postvoid residual urine (PVR) and ﬂexible urethroscopy to
assess sphincter function and mobility of the membranous
urethra. The “repositioning test” [9, 13]w a su s e dt o
simulatethefunctionofmaleslingbeforeimplantation.Only
patientswithsphinctercontractionwithorwithoutcomplete
sphincter closure received an RTS. ICIQ-UI SF 2004 score, a
validated self-report questionnaire, was assessed to evaluate
urinary incontinence and its impact on quality of life.
Degree of incontinence was classiﬁed by the number of pads
used per 24 hours and categorized in 3 grades (mild: 1-2,
moderate:3–5;severe:>5pads/24h).Table 1 presentspatient
characteristics before sling implantation in detail.
Accordingtoaprospectiveprotocol,patientswerereeval-
uated after 3, 6, and 12 months concerning the number of
pads used daily, the current ICIQ-UI SF score, Qmax,a n d
PVR. Cure was deﬁned as no pad usage, improvement was
deﬁned as a use of 1-2 pads/day or ≥50% reduction of the
preoperative pad use. Treatment was deﬁned as success if
patients were either cured or improved. All complications
were recorded and assessed from review of the patients’
clinical record charts.
2.1. Surgical Treatment. The surgical implantation of male
sling was performed as described before [7]. Intraoperative
urethroscopy was performed in all cases to validate correct
sling placement and to exclude urethral lesions. All sling
implantations were performed by one surgeon (F.J.).
2.2.StatisticalDataAnalysis. SPSS17.0softwarewasusedfor
statistical analysis. Quantitative values were compared using
the Mann-Whitney U-test. Chi-square tests were performed
to compare the success and failure groups by demographic,
clinical, surgical, and follow-up parameters. An error proba-
bility of P<0.05 was deﬁned as the signiﬁcance limit.
3. Results
The median followup was 9 months (range, 3–14). Based on
pad test results at last followup the cure rate (no pad usage)
was 56.3% (18 of 32 patients). The improvement rate (1-2
pads/day or ≥50% reduction) was 21.9% (7 patients). No
improvement was seen in 21.9% (7 patients). The success
rate was durable since only one patient initially classiﬁed
as cured at the 3-month visit subsequently had to use pads
again in the course of followup. Patients with severe SUI
(n = 8) showed a trend of inferior cure rates compared to
patients with mild (n = 6) and moderate (n = 18) SUI;
however, this was not signiﬁcant (25% versus 83.3% and
61.1%, P = 0.075, Fisher’s exact test) (see Table 2). Overall
mean ± SD pad use decreased from 5.1 ± 2.8 (median: 4,
range: 2–10) to 1.8 ± 2.7 (median: 0, range: 0–10) pads
daily (P<0.001, U test). The ICIQ-UI SF score improved
f r o mam e a no f1 5 .4 ± 3.5 (median: 16, range: 7–21) before
sling implantation to 5.7 ± 6.3 (median: 4, range: 0–18)
after surgery (P<0.001; U test) (see Table 3). Twenty-one
patients (65.2%) demonstrated a 50% reduction or more
of the ICIQ-UI SF score after sling implantation. The 50%
decrease of daily pad use was signiﬁcantly associated with
the 50% decrease of ICIQ-IU SF score indicating a strong
correlation between both parameters (P<0.001, Fisher’s
exact test).
Toevaluatethepotentialimpactofpriortreatmentonthe
sphincter region and thus success of the RTS implantation
several subgroup analysis was performed.
Patients with prior pelvic radiotherapy (n = 10, 31.3%)
demonstrated a cure rate of 30% (n = 3/10) and an
improvement rate of 30% (n = 3/10), respectively. The
failure rate in patients with prior radiotherapy was 40%
(n = 4/10). The ICIQ-UI SF score was decreased by ≥50%
in 40% of these patients. However, there was no statisticalISRN Urology 3
Table 2: Postoperative results at maximum followup.
All patients Patients with mild
incontinence (n)
Patients with moderate
incontinence (n)
Patients with severe
incontinence (n)
N = 32 N = 6 N = 18 N = 8
Success rate† 78.2% (25) 83.3% (5) 83.3% (15) 62.5% (5)
Cure rate 56.3% (18) 83.3% (5) 61.1% (11) 25.0% (2)
Improved rate 21.9% (7) — 22.2% (4) 37.5% (3)
Failed 21.9% (7) 16.7% (1) 16.6% (3) 37.5% (3)
†success rate = cure rate + improved rate.
Table 3: Results of RTS treatment at maximum followup.
Variable Before sling
implantation
After sling
implantation
Daily pad use, pads/day
Median (range) 4 (2–10) 0 (0–10)†
Mean 5.06 1.75
ICIQ-UI SF score
Median (range) 16 (7–21) 4 (0–18)‡
Mean 15.39 5.65
PVR∗,m L
Median (range) 0 (0–40) 0 (0–70)§
Mean 7.33 11.00
Maximum uroﬂowmetry, mL/s
Median (range) 21.9
(2.3–53.6)
17.2
(5.9–43.4)¶
Mean 23.97 20.33
∗postvoid residual urine
†U-Test; P<0.001
‡U-Test; P<0.001
§U-Test; P = 0.381
¶U-Test; P<0.001.
diﬀerenceregardingpaduseandICIQ-UISFscorecompared
to patients without prior radiotherapy (≥50% pad reduction
60.0% versus 81.8%, P = 0.218 and ≥50% ICIQ-UI SF
score decrease. 44.4% versus 77.3%P = 0.105, respectively;
without prior radiotherapy’s exact test).
Considering patients with previous or simultaneous
transurethral incision of the bladder neck (n = 10, 31.3%)
the cure rate was 30%, the improvement rate 20%, and the
failure rate 50%. Again, there was a trend towards worse
outcome regarding decrease of daily pad use compared
to patients without transurethral incision (≥50%; 50.0%
versus 86.8%; P = 0.072, Fisher’s exact test). However, the
reduction of ICIQ-UI SF score demonstrated a signiﬁcantly
worse outcome in these patients (≥50%; 33.3% versus
81.8%; P = 0.015, Fisher’s exact test). Neither pretreatment
withbulkingagentsnorpatientage(≥70yrs.versus<70yrs.)
had impact on improvement of pad use or ICIQ-UI SF score
after sling implantation.
No changes in postvoid residual urine (PVR) were ob-
servedaftertheimplantationoftheRTS(mean:7.3±12.8mL
versus 11.0 ± 19.0mL; P = 0.381, U test). Uroﬂowmetry
demonstrated signiﬁcant decreased Qmax rates (mean: 20.3±
11.9v e r s u s2 3 .9 ±13.6mL/sec) after sling implantation (P<
0.001, U test). Table 3 summarizes these events.
3.1. Adverse Events. No perioperative serious complications
occurred. In one patient the RTS had to be removed
because of sling dislocation and persistent perineal pain.
The patient had undergone prior pelvic radiotherapy and
palliative transurethral laser resection before sling implanta-
tion. Postoperative acute urinary retention (AUR) was seen
in ﬁve patients (15.6%). All of these patients were treated
with a transurethral catheter. In all cases the catheter could
be removed after 1–3 weeks without further treatment with
residual urine ≤50mL at time of catheter removal. 3 patients
(9.3%) had mild local wound infection/inﬂammation and
were treated conservatively with oral antibiotics.
4. Discussion
Several reports described promising results of RTS implan-
tation on postprostatectomy urinary stress incontinence. [7,
9, 10, 13, 14]. Midterm outcome in a recent study showed
sustainable results over a followup period of up to two years
[15]. The cure rate ranged between 51–73% in previous
studies [9–11, 16–18]. Most common complications of the
male sling are urinary retention, impaired healing, and sling
dislocation due to inﬂammation or misplacement [13, 19].
In our present study the cure rate was 56.3%. Moreover,
in 21.9% of the patients the incontinence was signiﬁcantly
improved. Considering these data, implantation of RTS
is a valid procedure for treatment of postprostate-surgery
incontinence. The signiﬁcant decrease of the ICIQ-UI SF
score from a median of 15.4 before sling implantation to 5.7
after surgery underscores this observation. Most common
complications were acute urinary retention in 15.6% and
wound healing disorders in 9.3%. Both occurrences were
treated conservatively. One patient underwent sling removal
because of dislocation of the sling system and persistent
perineal pain. While acute urinary retention was a transient
postoperative observation, mild reduction of Qmax was a
common ﬁnding after male sling implantation in our study
suggesting that the implantation and function of the RTS
result at least partly in obstruction. In contrast to our
observation urodynamic evaluation performed in previous
studies had not revealed signiﬁcant changes of maximum
ﬂow rates following sling implantation [15, 16]. However,
in the present study the clinical impact of the reduced4 ISRN Urology
Qmax could almost be disregarded. Residual urine volume
demonstrated no signiﬁcant change after sling implantation
and urinary frequency seemed to be unaﬀected.
Most accurate means of predicting treatment success and
subsequent selection of appropriate patients for functional
transobturator sling implantation are still under debate.
In the present study severity of incontinence showed a
trend to negative impact on the cure rate. This observation
was found to be signiﬁcant in a few studies [10, 11, 20,
21], whereas no correlation was found in other reports
[9, 12]. Even though the cure rate was only 25% in patients
with severe SUI, the present success rate (cure rate +
improvement rate) of 62.5% in this challenging cohort
demonstrates that patients with severe incontinence can
beneﬁtfromslingimplantation.Nevertheless,precisepatient
information about the decreased cure rate is needed if male
sling implantation is the chosen treatment in these patients.
Although our results are hampered by the small number
of cases, analysis of patients with history of radiation therapy
showed a tendency of worse outcome in terms of pad use
and ICIQ-UI SF score, respectively. This observation is in
line with Cornu et al. who noticed in patients with prior
radiotherapy (n = 17) a success rate of 59% (9 cured, 1
improved) compared to 85% in patients without history
of pelvic radiation indicating that prior radiation could
predict inferior clinical outcome [10]. In a prospective study
Bauer et al. reported similar results with a success rate of
50% (25% cure rate, 25% improvement rate) in selected
patients (n = 24) after radical prostatectomy and adjuvant
radiotherapy [22]. One explanation for the worse outcome
in these patients might be a direct radiogenic damage of
the intrinsic sphincter in combination with an increasing
immobility of the urethra caused by the irradiated tissue in
the perineal area [22].
Moreover, patients with previous or simultaneous anas-
tomotic stricture surgery (n = 10) showed a trend
towards inferior outcome regarding decrease of daily pad
use compared to patients without history of urethral surgery
(50.0% versus 86.8%). Additionally, the ICIQ-UI SF score
demonstrated a signiﬁcant worse outcome in these patients
(≥50% reduction; 33.3% versus 81.8%). This corresponds
to midterm results reported by Cornu et al. on a subgroup
of 18 patients with a history of surgery for urethral stenosis
demonstrating a signiﬁcant association with persistent pad
use after sling implantation [20]. The lower success rate in
patients with prior transurethral surgery may be caused by
the immobility of a “stiﬀ” low compliant proximal urethra
resulting from intrinsic scar tissue. Our study indicates
that prior therapy with potentially negative impact on the
urethral mobility has a negative inﬂuence on treatment
success. Therefore, in this challenging cohort we recommend
using the functional treatment approach of the RTS very
cautiously.
The limitation of our study is certainly the low number
of patients with a mean followup of 9 months after im-
plantation. Long-term prospective studies with focus on
risk factors of treatment failure after RTS implantation are
warranted to prove real value.
5. Conclusions
The retrourethral transobturator male sling represents a safe
andeﬀectivetreatmentoptionforpatientswithpostprostate-
surgery SUI. History of radiotherapy and urethral surgery as
well as severe incontinence should be carefully considered in
the preoperative selection of patients since in this subgroup
the success rate of AdVance male sling implantation could be
lower.
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